Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

BusinesswireNov 14 20:30

Press Release: Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Dow JonesNov 13 20:34

Cybin Inc: INTERIM MDA EN

SEDARNov 13 20:31 · Announcements

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression

BenzingaNov 13 20:31

Cybin Inc: INTERIM FINANCIAL STATEMENTSREPORT EN

SEDARNov 13 20:30 · Announcements

EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program

BenzingaOct 24 19:01